Dopavision, an innovative company committed to developing cutting-edge technologies and treatments for myopia, has just announced the launch of its MyopiaX-1 clinical trial centres.
The randomised, active-controlled clinical trial aims to assess the safety, tolerability, and potential clinical impact of MyopiaX, a smartphone application created to address myopia progression in children and adolescents. By integrating the app with a virtual reality headset and a Bluetooth controller, MyopiaX provides a unique, tailored and non-invasive option for myopia control.
The company's expertise lies in leveraging the role of the neurotransmitter dopamine, which plays a crucial part in regulating the elongation of the eye during myopia progression. By harnessing the potential of dopamine and the knowledge of renowned experts in ophthalmology, Dopavision has developed a solution that allows parents to monitor and manage their child's myopia progression conveniently.
“MyopiaX is designed as a non-invasive therapy to trigger an increase in the eye’s natural production of dopamine, a molecule known to be involved in regulating eye growth,”
said Mark Wuttke, CEO of Dopavision.
The MyopiaX-1 Clinical Trial:
The trial represents a significant step forward in advancing myopia treatment whilst also validating the effectiveness and safety of MyopiaX. The trial's active sites, spread across various locations, including the UK, are diligently working to gather valuable data that will shape the future of myopia treatment.
Dopavision's MyopiaX-1 Clinical Trial will enrol children with progressive myopia between the ages of 6 and 12 years and a refractive error between –0.75D and –5.00D.
The significance of the MyopiaX-1 Clinical Trial lies in its potential to transform the landscape of myopia management. By rigorously studying the impact of the MyopiaX-1 system on myopia progression, the trial seeks to provide clinicians and individuals with valuable insights into a novel treatment approach.
Some people may find the therapy counterintuitive, based on some of the other theories of what leads to eyeball growth in myopia. However, the science behind the device seems robust and clinical trials will help shed more light on the therapy.
Prof. Ian Flitcroft and Prof. James Loughman from the Centre for Eye Research Ireland and Myopia Focus Advisory Committee members lead the coordinating centre of the MyopiaX-1 clinical protocol. The first results of the study are expected to be released in early 2024.
Read the full article here